



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

13 February 2012
EMA/CVMP/126726/2007
Committee for Medicinal Products for Veterinary Use (CVMP)

Reflection paper on risk management plans for centrally authorised veterinary medicinal products

Draft Agreed by PhVWP-V	July 2007
Adoption by CVMP for release for consultation	12 November 2009
Start of public consultation	12 November 2009
End of consultation (deadline for comments)	31 March 2010
Agreed by PhVWP-V	January 2012
Adoption by CVMP	9 February 2012



Reflection paper on risk management plans for centrally authorised veterinary medicinal products

1. Introduction (background)	3
2. Discussion	3
2.1. Definition and scope of a risk management system	3
2.2. Scope.....	4
2.3. Suggested contents of the description of the risk management system (risk management plan)	4
2.4. Initiation, submission, evaluation and termination of risk management plans.....	5
2.5. Communication.....	6
3. Conclusion	6
4. References	7

1. Introduction (background)

The current legislation foresees that the applicant may need to develop and describe in detail a risk management system for inclusion in the application before a marketing authorisation can be granted for a medicinal product for veterinary use.

Article 31(1) of Regulation (EC) 726/2004 (Ref. 1) refers to Art 12(3) of Directive (No) 2001/82/EC, (Ref.2), that sets the requirement for a risk management system stating that the application for a marketing authorisation shall contain, in particular, the following information:

(k) a detailed description of the pharmacovigilance system, and, where appropriate, the risk management system that the applicant will put in place.

Veterinary pharmacovigilance is in continuous development. The provision for risk management systems is new in the field of veterinary medicines and therefore gives opportunity for novel, targeted and risk-based approaches to take place in the monitoring and management of safety of authorised medicinal products for veterinary use, as appropriate. The legal provision for risk management plans was originally developed in response to safety issues arising from the use of human medicinal products and marketing authorisation holders (MAHs) of medicinal products for human use are required to submit risk management plans as a routine part of all marketing authorisation applications. The situation is not the same with respect to veterinary medicines. The need for risk management plans is less evident in the absence of major post authorisation safety issues. For this reason further reflections and consideration are needed prior to implementation of the legal provision to benefit all involved stakeholders including the applicants, MAHs, the competent authorities in the European Union (EU) regulatory network and the general public.

2. Discussion

The risk management system is intended to become a systematic tool for providing data on risks and solutions for controlling those risks. Such data are intended for consideration and maintenance of a favourable benefit-risk balance for products, when appropriate (Ref.3).

The following elements of the risk management system need consideration and establishment:

- the definition of the risk management system,
- the scope, and the risk types that this system is designed to address,
- the expected contents of the description of the risk management system (risk management plan),
- the initiation, practical submission, maintenance and termination of the risk management plan; and
- communication.

2.1. Definition and scope of a risk management system

The risk management system is defined as:

a set of pharmacovigilance activities and interventions designed to identify, characterise, prevent or minimise risks relating to a medicinal product, including the assessment of the effectiveness of those activities and interventions.

While this definition is identical for medicinal products for veterinary and human use (Ref.4), the practical implementation should consider the particularities of veterinary medicines.

2.2. Scope

Experience on effective pharmacovigilance activities is continuously gained throughout the EU. Information on the functioning of the system is, however, scattered. At present, CVMP considers that it is appropriate to limit the scope to very special products for which the need for special arrangements is obvious i.e. situations where there are identified *potential or actual* risks that cannot be managed through routine measures or pharmacovigilance. These situations might most often be related to products with certain types of risks, e.g. known user safety risks or risks to the environment, or to products authorised under exceptional circumstances.

The *potential or actual risks* leading to the need for a risk management system would, however, need to be clarified in detail.

Existing guidelines (Ref.5) and additional CVMP recommendations should be used as far as possible for planning and executing the targeted pharmacovigilance activities.

Experiences with the use of risk management systems should be systematically collected by the CVMP to evaluate the effect and value of the recommendations concerning risk management systems.

2.3. Suggested contents of the description of the risk management system (risk management plan)

The following elements describe four parts of a possible risk management plan:

1. Identify known and potential risks whether product or class-related, as well as areas lacking data and conclude on the existence of *specific* safety issues (safety specification):

The approved summary of product characteristics (SPC) serves as a reference document - a safety specification – in signal detection on e.g. periodic safety update report (PSUR) data. The SPC is, however, limited to the information on known risks (animal adverse reactions and human reactions, environmental effects) and agreed risk management measures (e.g. contraindications, precautions for use). For future signal detection for veterinary medicinal products, discussions on the use of an extended safety specification have been initiated. This safety specification would summarise information on risks not only from the approved SPC but also from other documents relevant to the marketing authorisation.

2. Define those specific activities that complement routine pharmacovigilance and that address the *specific* safety issues, if any (pharmacovigilance plan):

For veterinary medicinal products, the pharmacovigilance plan could be limited to statements on the need for collection of specific data from targeted groups of animals for instance in post-marketing surveillance studies conducted by the MAH on the basis of the opportunity given by legislation¹. The collection may be triggered on the basis of the guideline on a strategy for triggering pharmacovigilance investigations preceding regulatory actions by EU competent authorities (Ref.6). The collection could be guided by the guideline for the conduct of post-marketing surveillance studies of veterinary medicinal products (Ref.7).

¹ In accordance with Art 51 of Regulation EC (No) 726/2004, for a period of five years following the initial placing on the market in the Community, the Agency may request on justified grounds that the MAH arrange for specific pharmacovigilance data to be collected from targeted groups of animals.

3. Evaluate the need for risk minimisation activities for each specific safety issue:

An evaluation of the need for risk minimisation activities is usually already done by the applicant during the development process prior to initial authorisation. For instance, the final proposed formulation and packaging, as well as the proposed product literature and prescription status already reflect minimisation actions taken. At the time of authorisation any outstanding issues should be listed and additional risk minimisation activities proposed to be taken if post-authorisation experience confirms the risk to be a matter where more guidance, communication or other minimisation actions are needed.

4. Identify risk minimisation actions required and their objectives (risk minimisation plan).

A template could be developed for applicants and MAHs to harmonise submission of risk management plans and facilitate their assessment by competent authorities.

2.4. Initiation, submission, evaluation and termination of risk management plans

A product might become subject to the need for a risk management plan at any time throughout its life cycle.

A risk management plan may be provided with the initial marketing authorisation application or when significant changes to the marketing authorisation are applied for if any *potential or actual risks* are identified by the applicant.

In addition, requests for the provision or amendment of a risk management plan could be made on justified grounds during any procedure and in conjunction with assessment of pharmacovigilance data by the CVMP, if relevant risks emerge. The CVMP would decide on the acceptability of a provided risk management plan or whether such a plan is necessary, as applicable.

Risk management plans would be assessed when submitted and would contribute to the evaluation of the benefit-risk balance of the product. A delegation of assessment could be considered to ensure harmonisation, involving the CVMP Pharmacovigilance Working Party, in accordance with its given mandate (Ref.8).

The safety data and other information emerging from the actions described in a risk management plan would be assessed by the CVMP or, as appropriate, its Pharmacovigilance Working Party.

Existing risk management plans would be maintained and updated versions submitted in synchrony with PSURs.

A summary of conclusions would be prepared on a regular basis by the CVMP.

Once actions outlined in the risk management plan have been successfully completed, the plan would be terminated. Emerging risks may, as described above, lead to the development of a new risk management plan for the same product.

Procedures for communication between the competent authorities within the EU regulatory network are already in place to facilitate rapid exchange of information and to enable harmonised, simultaneous action in response to emerging data, as necessary. The rapid alert and non urgent information system would frequently be suitable.

2.5. Communication

Various aspects need to be considered and agreed concerning communication to the public on the contents of and outcomes stemming from risk management systems for all applicable products. These aspects would best be considered in a wider context covering overall pharmacovigilance communication.

3. Conclusion

Following the feedback received on this reflection paper and the experience to date, the CVMP considers it appropriate to limit the scope for requirement of risk management plans to specific veterinary medicinal products. These would be products in situations where there are identified potential or actual risks that cannot be managed or mitigated through routine measures or pharmacovigilance, in accordance with criteria to be set, or when requested, by the relevant competent authority to ensure that the benefit-risk balance remains favourable. There may be a need to provide recommendations to applicants and MAHs on the requirements, initiation, submission, maintenance and termination of detailed descriptions of risk management systems, when appropriate, which will continue to be done on a case by case basis.

Aspects on pharmacovigilance communication would best be considered in a separate overall communication plan on veterinary pharmacovigilance.

Experiences on the use of risk management plans by the CVMP will continue to be systematically collected to evaluate their effect and value.

This paper reflects the status of the current thinking of the CVMP on risk management plans for veterinary medicinal products and takes into account comments received during the public consultation. Although at present the framework provided in the reflection paper is considered to be sufficient, should the need arise and in light of experience gained, further guidance on risk management plans may be developed in future.

4. References

1. European Commission (2004): Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency http://ec.europa.eu/health/files/eudralex/vol-1/reg_2004_726_cons/reg_2004_726_cons_en.pdf
2. European Commission (2001): Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to veterinary medicinal products http://ec.europa.eu/health/files/eudralex/vol-5/dir_2001_82_cons2009/dir_2001_82_cons2009_en.pdf
3. Committee for Medicinal Products for Veterinary Use (2009): CVMP Recommendation on the evaluation of the benefit-risk balance of veterinary medicinal products (EMEA/CVMP/248499/07) http://www.ema.europa.eu/docs/en_GB/document_library/Other/2009/10/WC500005264.pdf
4. Committee for Medicinal Products for Human Use (2005): Guideline on Risk Management for Medicinal Products for Human Use (EMEA/CHMP/481362/2007)
5. European Commission (2011): Volume 9B of the Rules Governing Medicinal Products in the European Union - Guidelines on Pharmacovigilance for Medicinal Products for Veterinary Use http://ec.europa.eu/health/files/eudralex/vol-9/vol_9b_2011-10.pdf
6. Committee for Medicinal Products for Veterinary Use (2003): CVMP guideline on a strategy for triggering pharmacovigilance investigations preceding regulatory actions by EU competent authorities (EMEA/CVMP/900/03– FINAL) http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500004993.pdf
7. Committee for Medicinal Products for Veterinary Use (1999): Guideline for the conduct of post-marketing surveillance studies of veterinary medicinal products EMEA/CVMP/044/99 - FINAL http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500005043.pdf
8. The European Medicines Agency and the Heads of Medicines Agencies (2009): Mandate, objectives and rules of procedure for the CVMP Pharmacovigilance Working Party (PhVWP-V) (EMEA/CVMP/PhVWP/133883/2004-Rev.2) http://www.ema.europa.eu/docs/en_GB/document_library/Other/2010/02/WC500073665.pdf